- Raw materials
- Antibacterials
- Zorubicin
Zorubicin API Manufacturers & Suppliers
0 verified results
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Commercial-scale Suppliers
Join our notification list by following this page.
Click the button below to find out more
Click the button below to switch over to the contract services area of Pharmaoffer.
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Zorubicin | CAS No: 54083-22-6 | GMP-certified suppliers
A medication that serves as an anthracycline antineoplastic agent with potential broad-spectrum chemotherapy applications requiring stringent quality control for clinical and research use.
Therapeutic categories
Product Snapshot
- Zorubicin is an experimental injectable small molecule formulation
- It is primarily investigated for oncological applications
- The product has not yet received approval from major regulatory authorities such as the FDA or EMA
Clinical Overview
Anthracyclines typically exert antineoplastic effects by intercalating DNA strands and inhibiting topoisomerase II, which disrupts DNA replication and transcription in rapidly dividing cells. While Zorubicin is presumed to share this general class mechanism, explicit mechanistic or pharmacodynamic data is not currently specified for this drug.
Key absorption, distribution, metabolism, and excretion (ADME) parameters for Zorubicin remain to be comprehensively characterized. Given the drug’s experimental status, information on bioavailability, metabolic pathways, elimination half-life, and clearance in human subjects is limited or unavailable.
Safety and toxicity data specific to Zorubicin are also not well documented. Anthracycline-related toxicities commonly include myelosuppression, cardiotoxicity, and gastrointestinal effects; however, extrapolation of these risks to Zorubicin should be approached with caution due to the absence of confirmatory safety profiles.
Zorubicin remains an experimental agent without regulatory approval for clinical use under any notable brand names. Consequently, it is not established in standard oncological treatment protocols.
From an API sourcing and quality perspective, procurement of Zorubicin must adhere to stringent synthetic and purity standards characteristic of anthracycline antibiotics. Given the complexity of its polyketide structure and glycosidic linkages, manufacturers should ensure compliance with regulatory guidelines for active pharmaceutical ingredients, including verification of identity, assay, residual solvents, and absence of impurities to guarantee reproducible clinical and research-grade quality.
Identification & chemistry
| Generic name | Zorubicin |
|---|---|
| Molecule type | Small molecule |
| CAS | 54083-22-6 |
| UNII | V25F9362OP |
| DrugBank ID | DB11618 |
Formulation & handling
- Zorubicin, a small molecule anthracycline, is suitable for oral or injectable formulations depending on solubility and stability optimization.
- Its low water solubility requires formulation strategies to enhance bioavailability and ensure consistent dosing.
- Handling should consider the polyketide structure's potential sensitivity to light and oxidation during manufacturing and storage.
Regulatory status
Zorubicin is a type of Antibacterials
Antibacterials, a category of pharmaceutical active pharmaceutical ingredients (APIs), play a crucial role in combating bacterial infections. These APIs are chemical compounds that target and inhibit the growth or kill bacteria, helping to eliminate harmful bacterial pathogens from the body.
Antibacterials are essential for the treatment of various bacterial infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and more. They are commonly prescribed by healthcare professionals to combat both mild and severe bacterial infections.
Within the category of antibacterials, there are different classes and subclasses of APIs, each with distinct mechanisms of action and target bacteria. Some commonly used antibacterials include penicillins, cephalosporins, tetracyclines, macrolides, and fluoroquinolones. These APIs work by interfering with various aspects of bacterial cellular processes, such as cell wall synthesis, protein synthesis, DNA replication, or enzyme activity.
The development and production of antibacterial APIs require stringent quality control measures to ensure their safety, efficacy, and purity. Pharmaceutical manufacturers must adhere to Good Manufacturing Practices (GMP) and follow rigorous testing protocols to guarantee the quality and consistency of these APIs.
As bacterial resistance to antibiotics continues to be a significant concern, ongoing research and development efforts aim to discover and develop new antibacterial APIs. The evolution of antibacterials plays a crucial role in combating emerging bacterial strains and ensuring effective treatment options for infectious diseases.
In summary, antibacterials are a vital category of pharmaceutical APIs used to treat bacterial infections. They are designed to inhibit or kill bacteria, and their development requires strict adherence to quality control standards. By continually advancing research in this field, scientists and pharmaceutical companies can contribute to the ongoing battle against bacterial infections.
